Collegium Pharmaceutical, Inc. Selling, General and Administrative Expense
Collegium Pharmaceutical, Inc. (COLL) reported Selling, General and Administrative Expense of $106.59 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:SellingGeneralAndAdministrativeExpense · last filed 2026-08-06
- Collegium Pharmaceutical, Inc. selling, general and administrative expense for the quarter ending 2026-06-30 was $106.59M, a 44.76% increase year-over-year.
- Collegium Pharmaceutical, Inc. selling, general and administrative expense for the quarter ending 2026-03-31 was $86.35M, a 12.99% increase year-over-year.
- Collegium Pharmaceutical, Inc. selling, general and administrative expense for the quarter ending 2025-12-31 was $67.64M, a 7.21% increase year-over-year.
- Collegium Pharmaceutical, Inc. selling, general and administrative expense for the quarter ending 2025-09-30 was $67.10M, a 8.31% increase year-over-year.
- Collegium Pharmaceutical, Inc. selling, general and administrative expense for fiscal 2025 was $284.80M, a 35.39% increase from fiscal 2024.
- Collegium Pharmaceutical, Inc. selling, general and administrative expense for fiscal 2024 was $210.36M, a 32.13% increase from fiscal 2023.
- Collegium Pharmaceutical, Inc. selling, general and administrative expense for fiscal 2023 was $159.21M, a 7.54% decline from fiscal 2022.
- Collegium Pharmaceutical, Inc. selling, general and administrative expense for fiscal 2022 was $172.19M, a 44.74% increase from fiscal 2021.
| Period end | Selling, General and Administrative Expense 3 month | Selling, General and Administrative Expense 6 month | Selling, General and Administrative Expense 9 month | Selling, General and Administrative Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $106.59M 10-Q · filed 2026-08-06 | $192.94M 10-Q · filed 2026-08-06 | $260.58M derived: sum of 3 quarters · filed 2026-08-06 | $327.69M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $86.35M 10-Q · filed 2026-05-07 | $153.99M derived: sum of 2 quarters · filed 2026-05-07 | $221.09M derived: sum of 3 quarters · filed 2026-05-07 | $294.73M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $67.64M 10-K · filed 2026-02-26 | $134.74M derived: sum of 2 quarters · filed 2026-02-26 | $208.38M derived: sum of 3 quarters · filed 2026-08-06 | $284.80M 10-K · filed 2026-02-26 |
| 2025-09-30 | $67.10M 10-K · filed 2026-02-26 | $140.74M derived: sum of 2 quarters · filed 2026-08-06 | $217.16M 10-Q · filed 2025-11-06 | $280.25M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $73.64M 10-Q · filed 2026-08-06 | $150.06M 10-Q · filed 2026-08-06 | $213.15M derived: sum of 3 quarters · filed 2026-08-06 | $275.11M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $76.42M 10-Q · filed 2026-05-07 | $139.51M derived: sum of 2 quarters · filed 2026-05-07 | $201.47M derived: sum of 3 quarters · filed 2026-05-07 | $244.80M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $63.09M 10-K · filed 2026-02-26 | $125.05M derived: sum of 2 quarters · filed 2026-02-26 | $168.38M derived: sum of 3 quarters · filed 2026-02-26 | $210.36M 10-K · filed 2026-02-26 |
| 2024-09-30 | $61.95M 10-K · filed 2026-02-26 | $105.29M derived: sum of 2 quarters · filed 2026-02-26 | $147.27M 10-Q · filed 2025-11-06 | $180.21M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $43.34M 10-K · filed 2026-02-26 | $85.32M 10-Q · filed 2025-08-07 | $118.26M derived: sum of 3 quarters · filed 2026-02-26 | $153.56M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $41.98M 10-K · filed 2026-02-26 | $74.92M derived: sum of 2 quarters · filed 2026-02-26 | $110.22M derived: sum of 3 quarters · filed 2026-02-26 | $148.41M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $32.94M 10-K · filed 2025-02-27 | $68.24M derived: sum of 2 quarters · filed 2025-02-27 | $106.43M derived: sum of 3 quarters · filed 2025-02-27 | $159.21M 10-K · filed 2026-02-26 |
| 2023-09-30 | $35.30M 10-K · filed 2025-02-27 | $73.49M derived: sum of 2 quarters · filed 2025-02-27 | $126.27M 10-Q · filed 2024-11-07 | $164.30M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | $38.19M 10-K · filed 2025-02-27 | $90.97M 10-Q · filed 2024-08-08 | $129.00M derived: sum of 3 quarters · filed 2025-02-27 | $167.37M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | $52.77M 10-K · filed 2025-02-27 | $90.81M derived: sum of 2 quarters · filed 2025-02-27 | $129.18M derived: sum of 3 quarters · filed 2025-02-27 | $170.43M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | $38.03M 10-K · filed 2024-02-22 | $76.40M derived: sum of 2 quarters · filed 2024-02-22 | $117.66M derived: sum of 3 quarters · filed 2024-02-22 | $172.19M 10-K · filed 2025-02-27 |
| 2022-09-30 | $38.37M 10-K · filed 2024-02-22 | $79.63M derived: sum of 2 quarters · filed 2024-02-22 | $134.15M 10-Q · filed 2023-11-07 | $160.76M derived: sum of 4 quarters · filed 2024-02-22 |
| 2022-06-30 | $41.25M 10-K · filed 2024-02-22 | $95.78M 10-Q · filed 2023-08-03 | $122.38M derived: sum of 3 quarters · filed 2024-02-22 | $152.90M derived: sum of 4 quarters · filed 2024-02-22 |
| 2022-03-31 | $54.53M 10-K · filed 2024-02-22 | $81.13M derived: sum of 2 quarters · filed 2024-02-22 | $111.64M derived: sum of 3 quarters · filed 2024-02-22 | $142.01M derived: sum of 4 quarters · filed 2024-02-22 |
| 2021-12-31 | $26.60M 10-K · filed 2023-02-23 | $57.12M derived: sum of 2 quarters · filed 2023-02-23 | $87.48M derived: sum of 3 quarters · filed 2023-02-23 | $118.96M 10-K · filed 2024-02-22 |
| 2021-09-30 | $30.51M 10-K · filed 2023-02-23 | $60.88M derived: sum of 2 quarters · filed 2023-02-23 | $92.36M 10-Q · filed 2022-11-03 | $119.18M derived: sum of 4 quarters · filed 2023-02-23 |
| 2021-06-30 | $30.37M 10-K · filed 2023-02-23 | $61.84M 10-Q · filed 2022-08-04 | $88.67M derived: sum of 3 quarters · filed 2023-02-23 | $115.09M derived: sum of 4 quarters · filed 2023-02-23 |
| 2021-03-31 | $31.48M 10-K · filed 2023-02-23 | $58.30M derived: sum of 2 quarters · filed 2023-02-23 | $84.73M derived: sum of 3 quarters · filed 2023-02-23 | $114.05M derived: sum of 4 quarters · filed 2023-02-23 |
| 2020-12-31 | $26.82M 10-K · filed 2022-02-24 | $53.25M derived: sum of 2 quarters · filed 2022-02-24 | $82.57M derived: sum of 3 quarters · filed 2022-02-24 | $113.83M 10-K · filed 2023-02-23 |
| 2020-09-30 | $26.43M 10-K · filed 2022-02-24 | $55.75M derived: sum of 2 quarters · filed 2022-02-24 | $87.01M 10-Q · filed 2021-11-04 | $112.10M derived: sum of 4 quarters · filed 2022-02-24 |
| 2020-06-30 | $29.32M 10-K · filed 2022-02-24 | $60.58M 10-Q · filed 2021-08-05 | $85.67M derived: sum of 3 quarters · filed 2022-02-24 | $115.74M derived: sum of 4 quarters · filed 2022-02-24 |
| 2020-03-31 | $31.26M 10-K · filed 2022-02-24 | $56.35M derived: sum of 2 quarters · filed 2022-02-24 | $86.42M derived: sum of 3 quarters · filed 2022-02-24 | $115.36M derived: sum of 4 quarters · filed 2022-02-24 |
| 2019-12-31 | $25.09M 10-K · filed 2021-02-25 | $55.16M derived: sum of 2 quarters · filed 2021-02-25 | $84.10M derived: sum of 3 quarters · filed 2021-02-25 | $116.45M 10-K · filed 2022-02-24 |
| 2019-09-30 | $30.07M 10-K · filed 2021-02-25 | $59.01M derived: sum of 2 quarters · filed 2021-02-25 | $91.36M 10-Q · filed 2020-11-05 | $121.81M derived: sum of 4 quarters · filed 2021-02-25 |
| 2019-06-30 | $28.93M 10-K · filed 2021-02-25 | $61.29M 10-Q · filed 2020-08-05 | $91.74M derived: sum of 3 quarters · filed 2021-02-25 | $125.19M derived: sum of 4 quarters · filed 2021-02-25 |
| 2019-03-31 | $32.35M 10-K · filed 2021-02-25 | $62.80M derived: sum of 2 quarters · filed 2021-02-25 | $96.25M derived: sum of 3 quarters · filed 2021-02-25 | $127.53M derived: sum of 4 quarters · filed 2021-02-25 |
| 2018-12-31 | $30.45M 10-K · filed 2020-02-27 | $63.90M derived: sum of 2 quarters · filed 2020-02-27 | $95.18M derived: sum of 3 quarters · filed 2020-02-27 | $126.76M 10-K · filed 2021-02-25 |
| 2018-09-30 | $33.45M 10-K · filed 2020-02-27 | $64.73M derived: sum of 2 quarters · filed 2020-02-27 | $96.31M 10-Q · filed 2019-11-06 | $121.40M derived: sum of 4 quarters · filed 2020-02-27 |
| 2018-06-30 | $31.28M 10-K · filed 2020-02-27 | $62.86M 10-Q · filed 2019-08-07 | $87.95M derived: sum of 3 quarters · filed 2020-02-27 | $110.71M derived: sum of 4 quarters · filed 2020-02-27 |
| 2018-03-31 | $31.58M 10-K · filed 2020-02-27 | $56.67M derived: sum of 2 quarters · filed 2020-02-27 | $79.43M derived: sum of 3 quarters · filed 2020-02-27 | $101.49M derived: sum of 4 quarters · filed 2020-02-27 |
| 2017-12-31 | $25.09M 10-K · filed 2019-02-27 | $47.85M derived: sum of 2 quarters · filed 2019-02-27 | $69.91M derived: sum of 3 quarters · filed 2019-02-27 | $92.76M 10-K · filed 2020-02-27 |
| 2017-09-30 | $22.76M 10-K · filed 2019-02-27 | $44.82M derived: sum of 2 quarters · filed 2019-02-27 | $67.67M 10-Q · filed 2018-11-08 | $93.03M derived: sum of 4 quarters · filed 2019-02-27 |
| 2017-06-30 | $22.06M 10-K · filed 2019-02-27 | $44.91M 10-Q · filed 2018-08-08 | $70.28M derived: sum of 3 quarters · filed 2019-02-27 | $93.84M derived: sum of 4 quarters · filed 2019-02-27 |
| 2017-03-31 | $22.85M 10-K · filed 2019-02-27 | $48.21M derived: sum of 2 quarters · filed 2019-02-27 | $71.78M derived: sum of 3 quarters · filed 2019-02-27 | $91.95M derived: sum of 4 quarters · filed 2019-02-27 |
| 2016-12-31 | $25.37M 10-K · filed 2018-03-07 | $48.93M derived: sum of 2 quarters · filed 2018-03-07 | $69.11M derived: sum of 3 quarters · filed 2018-03-07 | $80.63M 10-K · filed 2019-02-27 |
| 2016-09-30 | $23.57M 10-K · filed 2018-03-07 | $43.74M derived: sum of 2 quarters · filed 2018-03-07 | $55.27M 10-Q · filed 2017-11-08 | $63.17M derived: sum of 4 quarters · filed 2018-03-07 |
| 2016-06-30 | $20.17M 10-K · filed 2018-03-07 | $31.70M 10-Q · filed 2017-08-09 | $39.60M derived: sum of 3 quarters · filed 2018-03-07 | $45.51M derived: sum of 4 quarters · filed 2018-03-07 |
| 2016-03-31 | $11.53M 10-K · filed 2018-03-07 | $19.43M derived: sum of 2 quarters · filed 2018-03-07 | $25.34M derived: sum of 3 quarters · filed 2018-03-07 | |
| 2015-12-31 | $7.91M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-07 | $13.81M derived: sum of 2 quarters · filed 2018-03-07 | $18.93M 10-K · filed 2018-03-07 | |
| 2015-09-30 | $5.91M 10-Q · filed 2016-11-10 | $11.03M 10-Q · filed 2016-11-10 | ||
| 2014-12-31 | $2.71M 10-K · filed 2017-03-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 | |
| Olema Pharmaceuticals, Inc. (OLMA) | United States | $0.790B | -5.35 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| Aclaris Therapeutics, Inc. (ACRS) | United States | $0.792B | -9.78 |
| GERON CORP (GERN) | United States | $0.803B | -12.14 |